Company intelligence / Profile preview

Mariana Oncology

Watertown, Massachusetts, United Statesmarianaoncology.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Mariana Oncology has developed a robust preclinical pipeline of novel peptide-based radioligand therapeutics targeting solid tumors with high unmet need. The lead candidate, MC‑339, an actinium-labeled peptidic small molecule for small cell lung cancer, was poised to enter clinical trials at the time of acquisition. The company’s approach aims for high tumor penetration and minimized toxicity through precision delivery of radiation. No clinical results have been reported yet.

Therapeutic areas: Oncology
Modalities: Radioligand therapiesPeptide-based radiopharmaceuticalsSmall molecules
Industry: Biotech

Partnerships

Previously independent; now integrated into Novartis’ oncology/radiopharmaceuticals division.Investors included Eli Lilly as strategic investor prior to acquisition.

Beyond the preview

Go deeper on Mariana Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mariana Oncology.

Explore the full profile